Our results reinforce the concept of leptin in the promotion of human malignancies and provide the rationale for additional studies aimed at verifying whether leptin signaling pathway may help to predict responses to endocrine therapies and could be exploited for the development of pinpoint alternative therapeutic strategies for the treatment of breast cancer patients, especially in the obese setting. The gene discussed is LEP; the disease is breast carcinoma.